Co-Diagnostics (CODX) Tops Q3 EPS by 9c

Co-Diagnostics (NASDAQ: CODX) reported Q3 EPS of ($0.20), $0.09 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $2.5 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Deutsche Bank Starts DexCom (DXCM) at Buy
• Co-Diagnostics hosts Saudi joint venture CoMira at Utah facility